|Bid||8.00 x 1000|
|Ask||16.15 x 800|
|Day's Range||15.04 - 16.05|
|52 Week Range||8.89 - 46.20|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 06, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.50|
MedAvail Holdings, Inc. (Nasdaq: MDVL) ("MedAvail"), a technology-enabled retail pharmacy company, today announced that TMCOne has continued to expand its relationship with MedAvail with the opening of its third clinic with an embedded SpotRx MedCenter. SpotRx Pharmacy is the retail pharmacy brand owned and operated by MedAvail in the United States, which deploys and operates the MedAvail MedCenters.
MYOS CORP ("MYOS" or the "Company"), a research-based advanced nutrition company with divisions that address both Human Nutrition and Animal Health, announced today that it has been granted United States Patent #10,925,904 by the United States Patent and Trademark Office (USPTO). The new patent, titled "Methods and Compositions for Improving Skeletal Muscle Protein Fractional Synthetic Rate," protects advanced technologies related to improving skeletal muscle protein synthetic rate in older mammals through the administration of proprietary nutritional compositions such as MYOS' advanced nutrition product, Fortetropin®.
Today we will run through one way of estimating the intrinsic value of MedAvail Holdings, Inc ( NASDAQ:MDVL ) by taking...